Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence.


Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
03 2020
Historique:
received: 18 12 2018
revised: 05 12 2019
accepted: 29 12 2019
pubmed: 18 1 2020
medline: 5 5 2021
entrez: 18 1 2020
Statut: ppublish

Résumé

People who inject drugs (PWID) are at elevated risk of HIV infection. Data on population sizes of PWID living with HIV are needed to inform the implementation of prevention, treatment and care programs. We estimated national population sizes of people who recently (past 12 months) injected drugs living with HIV and evaluated ecological associations with HIV prevalence in PWID. We used national data on the prevalence of injecting drug use and of HIV among PWID, derived from systematic reviews, to estimate national population sizes of PWID living with HIV. Uncertainty was estimated using Monte Carlo simulation with 100,000 draws. We extracted data on sample characteristics from studies of HIV prevalence among PWID, and identified national indicators that have been observed or hypothesised to be associated with HIV prevalence in PWID. We used linear regression to evaluate associations between these variables and HIV prevalence in PWID. Four countries comprised 55% of the estimated global population of PWID living with HIV: Russia (572,500; 95% uncertainty interval (UI) 235,500-1,036,500); Brazil (462,000; 95% UI 283,500-674,500); China (316,500; 95% UI 171,500-493,500), and the United States (195,500; 95% UI 80,000-343,000). Greater anti-HCV prevalence and national income inequality were associated with greater HIV prevalence in PWID. The countries with the largest populations of PWID living with HIV will need to dramatically scale up prevention, treatment and care interventions to prevent further increases in population size. The association between anti-HCV prevalence and HIV prevalence among PWID corroborates findings that settings with increasing HCV should implement effective interventions to prevent HIV outbreaks. The association between income inequality and HIV among PWID reinforces the need to implement structural interventions alongside targeted individual-level strategies.

Sections du résumé

BACKGROUND
People who inject drugs (PWID) are at elevated risk of HIV infection. Data on population sizes of PWID living with HIV are needed to inform the implementation of prevention, treatment and care programs. We estimated national population sizes of people who recently (past 12 months) injected drugs living with HIV and evaluated ecological associations with HIV prevalence in PWID.
METHODS
We used national data on the prevalence of injecting drug use and of HIV among PWID, derived from systematic reviews, to estimate national population sizes of PWID living with HIV. Uncertainty was estimated using Monte Carlo simulation with 100,000 draws. We extracted data on sample characteristics from studies of HIV prevalence among PWID, and identified national indicators that have been observed or hypothesised to be associated with HIV prevalence in PWID. We used linear regression to evaluate associations between these variables and HIV prevalence in PWID.
RESULTS
Four countries comprised 55% of the estimated global population of PWID living with HIV: Russia (572,500; 95% uncertainty interval (UI) 235,500-1,036,500); Brazil (462,000; 95% UI 283,500-674,500); China (316,500; 95% UI 171,500-493,500), and the United States (195,500; 95% UI 80,000-343,000). Greater anti-HCV prevalence and national income inequality were associated with greater HIV prevalence in PWID.
CONCLUSION
The countries with the largest populations of PWID living with HIV will need to dramatically scale up prevention, treatment and care interventions to prevent further increases in population size. The association between anti-HCV prevalence and HIV prevalence among PWID corroborates findings that settings with increasing HCV should implement effective interventions to prevent HIV outbreaks. The association between income inequality and HIV among PWID reinforces the need to implement structural interventions alongside targeted individual-level strategies.

Identifiants

pubmed: 31951926
pii: S0955-3959(19)30369-X
doi: 10.1016/j.drugpo.2019.102656
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102656

Subventions

Organisme : Department of Health
ID : RP-DG-0610-10055
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K006525/1
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG-0616-20008
Pays : United Kingdom
Organisme : NIDA NIH HHS
ID : R01 DA037773
Pays : United States
Organisme : Medical Research Council
ID : MR/K023233/1
Pays : United Kingdom

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Sarah Larney (S)

National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney 2052, NSW Australia. Electronic address: s.larney@unsw.edu.au.

Janni Leung (J)

National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney 2052, NSW Australia.

Jason Grebely (J)

Kirby Institute, UNSW Sydney, Sydney NSW Australia.

Matthew Hickman (M)

Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Peter Vickerman (P)

Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Amy Peacock (A)

National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney 2052, NSW Australia.

Jack Stone (J)

Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Adam Trickey (A)

Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Kostyantyn V Dumchev (KV)

Ukrainian Institute for Public Health Policy, Kiev, Ukraine.

Samantha Colledge (S)

National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney 2052, NSW Australia.

Evan B Cunningham (EB)

Kirby Institute, UNSW Sydney, Sydney NSW Australia.

Michael Lynskey (M)

National Addiction Centre, King's College London, London, United Kingdom.

Richard P Mattick (RP)

National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney 2052, NSW Australia.

Louisa Degenhardt (L)

National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney 2052, NSW Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH